The human papillomaviruses (HPVs) are a diverse group of infectious agents, some of which are a causative agent of human cancers. Cervical cancer and oral cancer are closely associated with specific types of HPV, and the tumors grow only if there is continual expression of the viral E6 and E7 genes. Evidence from in vitro studies shows that when expression of these genes is inhibited by gene therapy approaches such as antisense RNA, ribozymes, or siRNA, the transformed phenotype of the cells is lost. Although it seems possible that clinical applications of this approach could help in the management of cervical and oral cancers there have been no clinical trials of gene therapy for HPV-associated cancers. Since the basic information is now available, a shift to translational research would be greatly welcomed.
Introduction
The last 30 years have seen the discovery of many types of papillomavirus as well as the demonstration of their role in human cancer and their significance as targets for diagnosis and therapy.
1 These viruses comprise a large variety of small DNA viruses, and they can infect many species. They were found originally in skin lesions of rabbits, which were shown to be both infectious and prone to malignant progression. 2 The human papillomaviruses (HPVs) were originally found in warts 3 and these are now known as the 'low-risk' HPVs. Related viruses were later found to be associated with some carcinomas and are known as the 'high-risk' HPVs. Between them the two groups of HPVs now comprise over 200 viral types and new ones are still being identified. 4 Essentially 100% of cervical cancers contain HPV of the high-risk types, and persistent infection of the cervix with these viruses is considered to be a necessary cause of cervical cancer. 5 Other ano-genital cancers also contain papillomaviruses in almost 90% of cases. 6 In addition to cervical cancer, there is reason to believe that oral cancer might have an etiological association with the high-risk HPVs. A meta-analysis of 94 reports concluded that HPV is indeed expressed more frequently in oral cancer than in normal oral mucosa, and should be considered as a risk factor. 7 A multinational study by the International Agency for Research on Cancer concluded that around 18% of oropharyngeal cancers contain high-risk HPVs. 8 The prognosis for patients that are diagnosed with HPV-associated carcinomas has not improved dramatically in recent years. For cervical cancer the 5-year survival rate has improved by only 4% over the last 25 years, and is now around 73%. For oral cancer the 5-year survival rate has improved by 5% over the same interval, but is still only around 59%. Screening programs for premalignant cervical lesions appear to have reduced the incidence of cervical cancer over the last few decades, but in the US there are still 10 000 cases and 3700 deaths per year. 9 For oral cancer, screening programs do not have a proven benefit 10 and there has been no recent reduction in the incidence, which remains at 30 000 cases with 7000 deaths. 9 Thus there is a clear need for improvements in prevention and management of HPV-associated cancers. The potential for gene therapy was reviewed here in the past, 11 and the 10th anniversary of that review seems to be an opportune time to re-examine the development of the field.
Mechanisms of malignant transformation by HPVs
As with most oncogenic DNA viruses, the high-risk HPVs encode proteins whose expression is continually needed for the cell to remain malignant. These are termed E5, E6 and E7. In the animal papillomaviruses other proteins are important but in humans it seems clear that these three, and especially E6 and E7, play the major role. The expression of these proteins is controlled from a region of the viral genome known as the Upstream Regulatory Region (URR), and the functions of this region are regulated by factors that are found mostly in epithelial cells. This explains the epithelial-specificity of HPVs. Expression from the URR is impaired by the viral E2 protein which prevents uncontrolled expression of transforming proteins in all infected cells.
After a prolonged premalignant infection, part of the HPV genome becomes integrated into the cell genome. The chromosomal site of integration is not specific, but the effect on the viral genome is to preserve the URR, the E6 and E7 genes, and the 5 0 end of the E2 gene. 4 In the malignant cell there is thus a permanent expression of the E6 and E7 RNAs and proteins, often with the aminoterminal part of the E2 protein.
The major effect of the E6 protein is the loss of the cellular protein p53. This happens through binding of E6 to p53, along with a variety of other proteins. p53 is then degraded by the cellular ubiquitin enzyme system. 12 The effect of the E7 protein is, with other factors, to bind the pRB protein. 13 This leads to degradation of the protein 14 and the release of transcription factors that are then free to transactivate the expression of cellular genes. In addition to the loss of functional p53 and pRB, the expression of HPV proteins causes other changes in the cell that are understood less well. These include the loss of DNA-repair pathways, leading to an increased rate of random mutations and chromosome damage. 15 These random changes result in some inconsistent effects in the cells, which can include upregulation of Notch ligand and Jagged 1 gene, and downregulation of a negativeregulator, Manic Fringe. 16 Those cervical and oral cancers that lack HPVs have rather different genetic changes. They usually have mutations in the p53 gene [17] [18] [19] as well as deletions of whole or large parts of chromosomes. 20 The resulting changes in the cell phenotype appear to be the same, but of course such cells would lack the HPV targets for gene therapy.
Vaccines
The recent development of vaccines for papillomaviruses has represented a major advance in preventive methods for human cancer. The basis of vaccines has been the observation that patients with cervical cancer have high levels of antibody to the L1 gene product of papillomaviruses, implying that the viral particle is exposed to the immune system at some point in the infection. Furthermore, papillomavirus infections of animals can be prevented by vaccination, using the L1 gene product as antigen. On this basis, two different human vaccines have been developed and tested in controlled clinical trials. Each has consisted of virus-like particles, which expose the immune system to L1 antigens from more than one HPV-type. Thus they could be expected to prevent infection by several HPVs but could not improve a response to tumor cells since the L1 gene is lost when the cells become transformed. Each vaccine was effective in reducing persistent infection with HPV and reducing the incidence of cervical abnormalities. 21, 22 It is thus expected that routine use of vaccines will soon be approved.
The result of vaccination will obviously depend on the degree to which it is put into use. It is likely that HPV vaccines will be restricted to adolescent females, and thus will not have any effect on HPV-associated cancers of males. Even in vaccinated females, it is unlikely that oral cancer could be reduced soon, since that cancer develops in middle age. 9 Questions have also been raised as to whether vaccines for sexually-associated diseases could be seen as providing excuses for promiscuity. Although this concern might slow their acceptance in some communities, it appears to be fairly limited at the present time. 23 It seems therefore that although a significant reduction in cervical cancer can be expected from vaccines, other methods of managing HPV-associated cancers will also be needed for the foreseeable future.
Established tumors might be treatable by an immune reaction to the E7 protein. One recent study has described the use of the bacterial adenylate cyclase protein of Bordetella pertussis to target dendritic cells with E7 in mice and thus cause rejection of grafted E7-expressing tumor cells. 24 
Gene therapy for HPV-associated cancers
With the causative nature of HPVs having become clear for several cancers, and with the molecular pathways having been described, it seems obvious that targets for gene therapy now exist and that the time has arrived to make practical use of the information. The essential features of HPV-associated cancers, and the possible ways that these could be used in gene therapy, are summarized in Figure 1 .
Decoys
The expression of the genes of HPV is controlled by factors that bind the viral URR, and therefore it is clear Figure 1 Gene therapy approaches to papillomavirus-transformed cancer cells. In tumor cells from HPV-associated cancers the virus sequences (green) are integrated into the cell chromosome (orange) in such a way as to preserve the URR, the E6 and E7 genes, and the 5 0 end of the gene for E2. The E2 truncated protein, together with cellular transcription factors, act on the URR to promote expression of E6, E7 and E2. The E6 and E7 genes prevent correct functioning of the p53 and pRB genes, respectively. Approaches to gene therapy (red) include: (1) Decoy proteins to inhibit the promoter/enhancer effects of the URR, (2) subversion of the URR to control expression of antitumor genes or replication of antitumor viruses, (3) blocking of the expression of E6 and E7 by antisense, ribozymes or siRNA, and (4) replacement of the missing p53 and pRB proteins.
that if decoy factors could bind to the URR in place of the specific factors, then expression of the viral oncogenes would stop. A major protein that binds this region is the E2 protein, and two research groups have shown that the E2 protein from the bovine papillomavirus can bind the URR but repress expression in the human cervical cancer cell line, HeLa. This arrests the growth of these cells in vitro. 25, 26 This seems to be a very promising, yet under-explored area for future research.
Subversion of the URR
Since the URR of papillomaviruses is specifically active in particular cell types, especially squamous carcinoma cells, it might be expected that the URR could be used to direct carcinoma-specific expression of genes that are therapeutic. The strength of the URR of HPV-16 and -18 is rather less than that of promoters from the human cytomegalovirus or the SV40 virus, but it is stronger than the promoters of the mouse mammary tumor virus or the human mdr-1 gene, all of which have been proposed for similar uses. 27 The URR does have the important advantage of showing specificity for squamous cells which the more potent promoters do not. Indeed, in one study, the URR was used to drive expression of the herpes simplex thymidine kinase gene in an adenovirus vector, and an effective suicide phenotype was conferred on the cancer cells. 27 An alternate use for the URR might be to control the replication of an oncolytic virus within a squamous cell carcinoma. One virus that could be used is the herpes simplex virus, which is a cytolytic virus whose natural host tissue is epithelium. When the promoter of an essential gene of herpes simplex virus type-1 was replaced with the URR of HPV-16 the resulting herpes/papillomavirus chimera replicated in oral cancer cells and killed them, but had significantly less toxicity for cells of other tissues. 28 This virus may have anticancer potential.
Blocking of viral gene expression
Since the main tumorigenic effects of the high-risk HPVs have been attributed to expression of the E6 and E7 genes, much of the effort to develop gene therapy for these infections has been directed at blocking their expression. Antisense RNA was the original method for specific blocking of the translation of RNA to protein. Small single-stranded antisense RNA molecules can bind RNA of the opposite strand, leading to a duplex, which is soon degraded. Thus there is a reduction in gene expression. The original HPV antisense constructs were expressed from plasmids that contained the E6 and E7 genes in the opposite orientation to the virus, relative to their promoter, and were tested in the C4-1 cervical cancer cell line. This indeed showed a loss of many features of transformed cells. 29 The observations were confirmed in other cervical cancer cells and in oral cancer cells that contained HPV sequences. 30 These studies established the feasibility of blocking expression and thus eliminating the malignant phenotype.
In addition to plasmid expression vectors that cause the antisense molecules to be synthesized in the cell, it is possible to use short antisense oligonucleotides, which are taken up by cells spontaneously. Such oligonucleotides will also inhibit the transformed phenotype of HPVcontaining cervical and oral cancer cells. 31 In addition to established cell lines, HPV antisense RNA has been shown to inhibit the growth of cervical cancer primary cells in culture. 32 In a mouse model it has been reported that intratumoral introduction of antisense RNA to E6 and E7 by an expression plasmid produced inhibition of tumor growth by downregulation of expression of E6 and E7. 33 Virus vectors have been used to transfer antisense molecules to cancer cells. For example, antisense sequences to HPV-16 E6/E7 were transferred to cervical cancer cells in one study using an adenovirus vector, and the transfected cells showed less tumorigenicity when transplanted to nude mice. 34 Similarly a retrovirus vector has been used to transfer antisense to E7 into the cervical cancer cell line CaSki, and this inhibited the expression of the E7 protein with upregulation of RB, downregulation of E2F-1, and inhibition of the tumorigenicity of the cells in nude mice. 35 Ribozymes were an advance on the use of antisense RNA, in that they comprise an antisense molecule with a secondary structure that provides the enzymatic ability to cleave the target molecule. Anti-HPV ribozymes are capable of digesting the E6/E7 RNA from HeLa cells although different target sites on the transcript show different susceptibilities. 36 The most effective ribozyme, targeted to a site at nucleotide 309 in the HPV-18 transcript, can inhibit the transformed phenotype of HeLa cells when expressed in the cells from a plasmid expression vector. 37 Others have shown that a hairpin ribozyme against the E6 region of the E6/E7 transcript prevents immortalization of cells by HPV-16. 38 However, even noncatalytic versions of the ribozyme have some effect, implying that the antisense component of their effect is critical, and the digestion of the target is less important.
In addition to HPV-16 and -18, a self-processing ribozyme that targets HPV-11 as well as the hepatitis B virus has been shown to reduce intracellular concentrations of the E6/E7 transcript of HPV-11. 39 The use of anti-HPV ribozymes seems to have been restricted to in vitro experiments, and practical applications are still awaited.
Another advance on the principle of antisense RNA and ribozymes is the development of small-interfering RNAs (siRNAs). These also lead to digestion of their target molecule, although by a different mechanism from ribozymes. Silencing of E6 and E7 mRNA transcripts by siRNAs has been shown to be feasible. 40 Silencing of E6 by siRNA caused apoptosis of HeLa cells in one study. 41 Another group did not find apoptosis from silencing E6 alone, but the cells did become more sensitive to the effects of chemotherapy. 42 In a different line of cervical cancer cells, silencing of E6 caused them to lose anchorage-independence and the cells made significantly smaller tumors in immunosuppressed mice. 43 Other approaches to the prevention of gene expression are possible, but have received less attention. The E6 protein itself might be blocked from functioning by an RNA molecule that binds it specifically, known as an aptamer. One group showed that this could cause apoptosis in HPV-16-positive cancer cells but not HPVnegative cells. 44 The aptamer was encoded by an expression-plasmid that was transfected into the cells. Thus, although this provides an alternative method of blocking the effects of E6 the method of delivery would be the same as for antisense, ribozyme or siRNA molecules. In another approach, the HPV E6 gene can be targeted directly by peptide nucleic acids. One group has shown that this approach may have potential 45 although the introduction of the peptide nucleic acid to the cell and to its molecular target does require some additional specialized methods.
There appear to have been no direct comparisons between the effects of antisense RNA, ribozymes, siRNA and the other approaches. Each seems to have its individual benefits and drawbacks. None have been reduced to clinical practice, or have yet been shown to have an effect on human carcinomas that are growing as animal xenografts.
Replacement therapy
Since the effects of E6 and E7 are the loss of function of p53 and pRB respectively, it seems likely that HPVassociated tumors could be controlled by replacement of wild-type p53 or pRB proteins in a functional form. This indeed can be done, but always results in uncontrolled overexpression of the proteins and death of the target cells. In cervical cancer cells the overexpression of p53 is toxic to the cells, independently of the presence of HPV genes. 46 Similarly in oral cancer cells the expression of p53 from an adenovirus vector has the effect of killing tumor cells regardless of the presence or absence of mutations in the p53 gene. 47, 48 The potential use of p53 or pRB as gene therapy has been examined for many types of cancers, quite apart from those that are associated with HPV, and has progressed to the stage of multiple human trials. 49 
Other approaches
The increase in the mutation frequency of cells that are infected by HPV leads to expression changes in many genes that might contribute to the malignant phenotype. Thus these genes provide novel targets for gene therapy, but might be restricted to sub-sets of tumors.
One such target is the Notch 1 protein, which complements the function of E6/E7 in the transformation of cells. Transformation is associated with the upregulation of the Notch ligand together with a protein known as Jagged 1, with simultaneous downregulation of a negative-regulator, Manic Fringe. Antisense to Notch 1 reduces the growth of the cervical cancer cell line CaSki when introduced in an adenovirus vector. siRNA to Jagged 1 also inhibits the tumorigenicity as does overexpression of Manic Fringe or expression of a dominant negative Jagged 1. 16 Thus this component of HPVassociated tumorigenicity might represent a target for gene therapy. In another interesting approach, efforts have been made to produce adenoviruses that replicate preferentially in HPV-transformed cells. This could be possible if replication-defective viral mutants could be complemented by HPV oncogenes. There are DNA-sequence similarities between the E7 protein of high-risk papillomaviruses and the pRB-binding regions, denoted CR1 and CR2, in the adenovirus E1A proteins. Thus, by deleting the CR1 and CR2 domains of an adenovirus, one mutant has been obtained that is reported to grow preferentially in raft cultures of human keratinocytes that were previously transfected with the E7 gene of HPV-18. 50 If this method can be developed further then it might produce a therapeutic virus that replicates in HPVassociated tumors, and thus be used in their treatment.
Delivery of anti-HPV gene therapy
As with many of forms of gene therapy, a significant problem, and possibly the most important problem, is the delivery of the therapeutic molecules into the tumor of a patient.
Since HPV-associated tumors always develop on a body surface, the most obvious way to transfer DNA to a primary tumor would be by physical application. One method of achieving this is to coat the DNA onto gold beads and propel them into tissue with compressed helium using a 'gene gun'. Since papillomavirus-associated cancers develop in basal epithelial cells, just a few cells below the surface, this is an attractive approach for the transduction of the target. However, early-generation gene guns have not shown sufficient efficiency, and until this is improved, it does not seem that physical transfer will be effective for treating human cancers. 51 Antisense oligonucleotides are simple constructs to deliver, and this can be accomplished by intravenous infusion. This has been shown successfully in cancer therapy for the blocking of expression of genes such as, for example, Bcl-2. Antisense oligonucleotides that target that gene have now been tested in several human trials. 52 It should be possible, therefore, to deliver antisense E6 or E7 RNA by intravenous infusion. Larger molecules, including ribozymes, cannot be delivered by intravenous infusion, and the gene that encodes them must be delivered directly to the tumor. This has not yet been found to be possible in the case of anti-HPV ribozymes. Indeed even expression of antisense RNA, which is effective when encoded by a plasmid vector, has not been found to be effective in cells that were infected with an adenovirus vector that carried the same expression cassette. The reasons for this are not known. Furthermore, solid tumors, such as oral cancers, are not well transfected by adenovirus vectors, and only cells around the needle track are well transduced. 47 Adeno-associated virus vectors can be used to deliver anti-E6/E7 antisense or ribozyme sequences to HeLa or SiHa cells, but injection into established SiHa tumors had no therapeutic effect. 53 The same vector was able to express the monocyte chemoattractant protein-1 and thus inhibit tumors, and therefore the vector itself was effective. The reason that the anti-E6/E7 sequences were not effective remains to be found, and this question represents a critical feature of the development of gene therapy for solid tumors. Adeno-associated virus does have the added advantage of having some intrinsic anti-HPV effects, even without any need for inserted anti-HPV sequences. 54 Although the mechanism for this is unknown, it could certainly increase the effectiveness of any gene therapy vector.
Despite recent progress and the various possibilities that have emerged, it still seems that there is no effective delivery mechanism for anti-HPV gene therapy, and this presents a problem at least as important as the specific targets and mechanisms.
Summary
Only a few human cancers are clearly associated with viruses, but the ones that are present very attractive targets for gene therapy. Cervical and other cancers that express HPV gene transcripts are dependent on these transcripts for their persistence. Exact molecular targets have been shown to exist and several approaches to their inhibition have been demonstrated. A stronger effort in translational research could produce effective cancer therapies in a short time.
